中研院稍早宣布武漢肺炎快篩試劑研發成功，篩檢時間將從現有的4小時大幅縮減到15分鐘，而且只會對新型冠狀病毒出現反應，檢驗更精準，預計 3 到 4 個月內可以開始量產！
以下是中研院的 Facebook 粉專貼文內容：
一句話，不解釋：#快篩 快來了！
1. 檢測時，直接揪出新冠病毒這個小壞壞！
2. 檢測時間：4小時縮短為15分鐘。
3. 加速量產流程中。
#學研單位COVID19抗疫平台 #最新研究進度
＿＿＿＿＿＿＿＿＿＿
⭐⭐⭐ 快篩裝置的關鍵試劑 ⭐⭐⭐
本院成功製造六親不認、只辨識新冠病毒（SARS-CoV-2）的檢測抗體
👉 破紀錄19天完成抗體篩選
本院基因體中心研究員楊安綏帶領團隊於 #19天 內完成針對新冠病毒核蛋白（N protein）抗體試驗。
🔥結果出爐：46株單株抗體中，其中 #有1株抗體 有極佳的單一辨識性，只對新冠病毒有反應，並不會與SARS、MERS病毒或其他導致一般感冒的冠狀病毒有交叉反應，快篩時可有效判別是否感染新冠病毒。透過此抗原檢測原型，量產後可將 #篩檢時間4小時縮短至15至20分鐘，快速提升檢疫需求！
👉 專利合成抗體庫群
至今並無檢測新冠病毒快篩免疫抗原的裝置，原因之一是開發 #側流免疫檢測LFIA 應用之關鍵抗體試劑需要數月之久。然而，楊安綏實驗室的 #合成抗體庫技術平台 剛好可快速提供大量新穎、具獨特性的針對各種蛋白質或胜肽等抗原的對應辨識抗體。
👉跨團隊接棒抗疫
廖俊智院長表示，2月初，本院研究人員便開始通力合作，快速合成新冠病毒核蛋白抗原，楊安綏團隊運用數十年來累積的技術，日以繼夜進行抗體合成及篩選，#比預期快二個月達成目標，令人振奮。
👉下一步？
在 經濟部 的安排下，將與廠商聯繫生產新冠病毒快篩抗原檢測的原型產品，將送食藥署驗證，獲得 衛生福利部 許可後，順利的話，希望廠商能在3到4個月內量產。廖院長強調，學研單位、廠商及衛福部仍需緊密溝通聯繫，以加快病人檢體的驗證，以便大規模臨床應用。
#測流免疫檢測 #自行合成抗體 #蛋白質檢驗 #比核酸檢驗更快
#前線防疫 #我們當堅實後盾 #新冠肺炎 #中研院 #AS
______
本院已建立國內學研單位「COVID-19合作平台」，此次成果也將會與平台共享，加速研發新冠肺炎快速篩檢工具、藥物與疫苗，合作抗疫。
🧐還不知道台灣有一群科學家早就組隊研究新冠病毒？
➡https://www.sinica.edu.tw/ch/news/6487
____
#幫研編轉傳英文版給你的外國親朋好友 #sharing #Taiwanresearch #ASresearch
Rapid Virus Detection! Academia Sinica develops antibodies for rapid immune-based test kit of SARS-COV-2 coronavirus
Currently available rtPCR-based SARS-COV-2 coronavirus diagnostic tests take about 4 hours to obtain results, with throughput limited by availability of laboratory facilities and trained personnel. To prevent the pandemic spread of the coronavirus, a faster way to detect infected patients is urgently needed. Today, Academia Sinica (AS) proudly announced that the first group of monoclonal antibodies specifically binding the coronavirus nucleocapsid protein (N protein) has been successfully generated and tested by Dr. An-Suei Yang and his team at the Genomics Research Center in AS. If successfully manufactured and validated, the rapid immune-based test kit could detect coronavirus in only 20 minutes, just like a rapid influenza test.
His team produced N proteins from 7 different viral species and screened against these to obtain a few dozen monoclonal antibodies. Out of these few dozen, one antibody against only SARS-COV-2 N protein, 9 against only SARS-COV N protein, and 36 against both SARS-COV-2 and SARS-COV N proteins were developed. One additional advantage, said Dr. Yang, is that none of these monoclonal antibodies bind any N proteins of the other 5 strains of coronavirus, thus cross-reactivity will not be a problem for the rapid SARS-COV-2 detection kit.
With the help of the Ministry of Economic Affairs, Dr. Yang’s team is working with manufacturers on the development and production of prototypes. In the coming months, they will discuss product validation and certification with the Taiwan Food and Drug Administration. They will then work with the Ministry of Health and Welfare to bring a rapid coronavirus test kit to Taiwan to combat this devastating epidemic.
#coronavirus #Rapidvirusdetection #antibody #SARSCOV2
